Lv5
854 积分 2025-08-25 加入
Outcomes and experience of anatomical partial lobectomy
9天前
已完结
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
14天前
已完结
Long-term outcomes of lobectomy vs. sublobectomy for stage I lung invasive mucinous adenocarcinoma
14天前
已完结
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
14天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
1个月前
已完结
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families
3个月前
已关闭
Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis
3个月前
已完结
Cancer treatment therapies: traditional to modern approaches to combat cancers
6个月前
已完结
Liposomes-enabled cancer chemoimmunotherapy
6个月前
已完结
皖公网安备34019202002308
